Join our team! Syntis Bio is seeking an accomplished leader to join as our Director of Development. Read more below and reach out if you're interested!
Syntis Bio
Biotechnology Research
Boston, Massachusetts 1,460 followers
A new paradigm in metabolic health
About us
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours. Syntis is headquartered in Boston.
- Website
-
https://syntis.bio
External link for Syntis Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
135 Morrissey Blvd
Boston, Massachusetts 02125, US
Employees at Syntis Bio
Updates
-
Syntis Bio reposted this
Syntis Bio Launches with $15.5M to Tackle Obesity and Rare Metabolic Diseases: https://lnkd.in/gZ5NyH29 #synbio
-
Syntis Bio reposted this
Over a year ago, I received tremendous support from this community when I shared that I was building something new. Your encouragement was truly humbling, as is the caliber of my co-founders at Syntis Bio – the brilliant physician-scientist Giovanni Traverso, and #RobertLanger, arguably the most successful entrepreneur in our industry. We've remained heads-down to focus on achieving key milestones that unlock Syntis' incredible potential. Today, I'm excited to officially introduce Syntis, a clinical-stage biopharma company developing oral therapies that harness the unique biology of the small intestine. None of this would be possible without the unwavering support of my co-founders, investors, advisors, and most importantly, my incredible team. I'm deeply grateful for the opportunity to bring Syntis' vision to life alongside such talented colleagues. Safar Partners, BOLD Capital Partners, Colorcon®, Touchdown Ventures, Portal Innovations, LLC. I invite you to read more about our mission and progress:
Today, we officially launch as Syntis Bio – a company with a mission to develop oral therapies that provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. With #obesity projected to affect 1.5 billion people by 2030, there is a significant demand for additional treatment options given ongoing issues with accessibility, cost, side effects and long-term maintenance. At Syntis, we look forward to rapidly advancing a portfolio of programs that address not only this global epidemic, but also metabolic diseases ranging from rare pediatric indications homocystinuria to maple syrup urine disease. Read more here: https://lnkd.in/e-Gd_PB5
-
-
Syntis Bio reposted this
I cannot thank Brad Loncar enough for taking an interest and providing far more thoughtful questions than the answers he received. If you would like to hear more about Syntis Bio, please tune in to BiotechTV.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Syntis Bio CEO Rahul Dhanda describes a novel obesity program that entered the clinic today and a broader platform that leverages the small intestine to impact metabolism and drug absorption. He describes the technology that Syntis uses to coat the upper region of the small intestine to modulate nutrient uptake, and the benefits this confers on metabolism and drug development. Full video: https://lnkd.in/gwXKgYux BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Syntis Bio reposted this
Congratulations to the official launch of Syntis Bio! We are excited to be a part of the journey with Rahul Dhanda and the rest of the Syntis Bio team.
Today, we officially launch as Syntis Bio – a company with a mission to develop oral therapies that provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. With #obesity projected to affect 1.5 billion people by 2030, there is a significant demand for additional treatment options given ongoing issues with accessibility, cost, side effects and long-term maintenance. At Syntis, we look forward to rapidly advancing a portfolio of programs that address not only this global epidemic, but also metabolic diseases ranging from rare pediatric indications homocystinuria to maple syrup urine disease. Read more here: https://lnkd.in/e-Gd_PB5
-
-
Today, we officially launch as Syntis Bio – a company with a mission to develop oral therapies that provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. With #obesity projected to affect 1.5 billion people by 2030, there is a significant demand for additional treatment options given ongoing issues with accessibility, cost, side effects and long-term maintenance. At Syntis, we look forward to rapidly advancing a portfolio of programs that address not only this global epidemic, but also metabolic diseases ranging from rare pediatric indications homocystinuria to maple syrup urine disease. Read more here: https://lnkd.in/e-Gd_PB5
-
-
Syntis Bio reposted this
I'm excited to moderate this exceptional panel of respected life science leaders (and a few friends). I hope you can join to share in their insights, which I know to be valuable from personal experience. Register now for this great opportunity to meet Douglas Fambrough, Andrew Hack, MD, PhD, Ritu Shah, PMP, and Jason Zuckerbrod as we discuss building companies and the relevant dynamics surrounding M&A.
Our April 23rd Portal Pours Boston panel is set! We have some of the brightest minds in life sciences and financing to discuss the value of planning for M&A. Thanks to all of our panelists - Douglas Fambrough (KCap Biotechnology Fund LP), Andrew Hack, MD, PhD (Bain Capital), Jason Zuckerbrod (Centerview Partners), Ritu Shah, PMP (ClostraBio, Inc), and Rahul Dhanda (Syntis Bio) for participating in our event. Also thank you to BioProcure, Inc./Prendio for sponsoring this event! Click the link below to learn more about the topics and to register: https://lnkd.in/gK7xZK89
Portal Pours Boston April Event
23230704.hs-sites.com
-
On #internationalwomensday, we at Syntis thank women across the globe for innovating every walk of life on earth. We are particularly grateful for the contributions, support, and commitment that the Women of Syntis have given their team and the company. We are fortunate and honored to share in their journey. #iwd2024
-
-
We’re #hiring a new Principal Scientist in Boston, Massachusetts. Apply today or share this post with your network.